<code id='76579B9E24'></code><style id='76579B9E24'></style>
    • <acronym id='76579B9E24'></acronym>
      <center id='76579B9E24'><center id='76579B9E24'><tfoot id='76579B9E24'></tfoot></center><abbr id='76579B9E24'><dir id='76579B9E24'><tfoot id='76579B9E24'></tfoot><noframes id='76579B9E24'>

    • <optgroup id='76579B9E24'><strike id='76579B9E24'><sup id='76579B9E24'></sup></strike><code id='76579B9E24'></code></optgroup>
        1. <b id='76579B9E24'><label id='76579B9E24'><select id='76579B9E24'><dt id='76579B9E24'><span id='76579B9E24'></span></dt></select></label></b><u id='76579B9E24'></u>
          <i id='76579B9E24'><strike id='76579B9E24'><tt id='76579B9E24'><pre id='76579B9E24'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:7
          Vertex Pharmaceuticals Inc. building
          Craig F. Walker/The Boston Globe

          Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease. 

          The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

          advertisement

          “The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          EMA weighs against approval for Mirati's lung cancer drug
          EMA weighs against approval for Mirati's lung cancer drug

          AdobeAEuropeanregulatorypanelhasrecommendedagainstapprovalofalungcancerdrugmadebyMiratiTherapeutics,

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          How Vertex's cystic fibrosis drug is changing patients' lives

          SusanUlan,right,greetshergranddaughterIvy,andherdaughterJessieAnderson,atAnderson'shome.SuzanneKreit